鮑氏不動桿菌肺炎藥物的全球市場：按藥物類別、給藥途徑和地區分類

全球鮑氏不動桿菌肺炎治療市場規模預計將從2023年的 6.146 億美元增加到2030年的 8.991 億美元，預測期內年複合成長率為 5.6%。

圖 1.2023年鮑氏不動桿菌肺炎治療藥物的全球市場佔有率（依地區分類）

鮑氏不動桿菌肺炎是一種由鮑氏不動桿菌屬細菌引起的一種嚴重肺炎。這些細菌常見於土壤和水中。近年來，多重抗藥性鮑氏不動桿菌桿菌引起的院內肺炎病例迅速增加。它通常影響免疫力缺乏的患者和在加護病房接受機械通氣的患者。抗生素抗藥性是鮑氏不動桿菌肺炎治療的一個主要問題。目前需要針對這種病原體的新治療方法。

市場動態：

全球鮑氏不動桿菌肺炎治療市場是由抗藥性菌株的流行和院內或人工呼吸器相關肺炎發病率的增加所推動的。根據美國疾病管制與預防美國，每年美國院內肺炎病例中，鮑氏不動桿菌感染疾病佔 8%至 10%。此外，有限的抗生素管道和缺乏專門針對鮑氏不動桿菌肺炎的核准治療方法為該市場帶來了機會。然而，高昂的開發成本和與新藥認證相關的監管障礙阻礙市場開拓。該市場受到多重抗藥性菌株發病率增加、診斷技術進步以及對有效治療方案的需求等因素的影響。製藥公司、研究機構和醫療保健提供者之間的合作在推動治療解決方案方面發揮關鍵作用。不斷變化的感染疾病情勢和 COVID-19 大流行的影響凸顯了透過創新治療性介入和公共衛生措施持續努力應對鮑氏不動桿菌肺炎的重要性。

本研究的主要特點

本報告對全球鮑氏不動桿菌肺炎治療市場進行了詳細分析，並提供了以2022年為基準年的預測期（2023-2030）的市場規模和年複合成長率（CAGR%）。

它揭示了各個細分市場的潛在收益成長機會，並為該市場說明了一系列有吸引力的投資提案。

提供了有關市場促進因素、限制因素、機會、新產品發布和核准、市場趨勢、區域前景、主要企業採取的競爭策略等的主要考察。

根據公司亮點、產品系列、主要亮點，實績和策略等參數對全球鮑氏不動桿菌肺炎治療藥物市場的主要企業進行了分析。

本報告的見解將使行銷人員和公司負責人能夠就未來的產品發布、升級、市場擴張和行銷策略做出明智的決策。

全球鮑氏不動桿菌肺炎治療藥物市場報告針對該行業的各個相關人員，如投資者、供應商、產品製造商、分銷商、新進業者和財務分析師。

透過用於分析全球鮑氏不動桿菌肺炎治療藥物市場的各種策略矩陣，將促進相關人員的決策。

目錄

第1章 研究目的與前提

• 研究目標
• 先決條件
• 簡稱

第2章 市場展望

• 報告說明
  • 市場定義和範圍
• 執行摘要
• Coherent Opportunity Map（COM）

第3章 市場動態、法規及趨勢分析

• 市場動態
• 影響分析
• 主要亮點
• 監管場景
• 服務交付組合
• PEST分析
• 波特的分析
• 併購場景
• 管道分析

第4章 全球鮑氏不動桿菌肺炎治療藥物市場 - 冠狀病毒（COVID-19）大流行的影響

• 新型冠狀病毒感染疾病（COVID-19）的流行病學
• 供需面分析
• 經濟影響

第5章 2018-2030年全球鮑氏不動桿菌肺炎治療藥物市場，依藥物類別

• 頭孢菌素
• 碳青黴烯類
• Aminoglycosides
• 多粘菌素

第6章 全球鮑氏不動桿菌肺炎治療藥物市場，依給藥途徑，2018-2030

• 口服
• 靜脈
• 其他

第7章 2018-2030年全球鮑氏不動桿菌肺炎治療藥物市場，依地區

• 北美洲
• 美國
• 加拿大
• 歐洲
• 德國
• 英國
• 西班牙
• 法國
• 義大利
• 俄羅斯
• 其他歐洲國家
• 亞太地區
• 中國
• 印度
• 日本
• 澳洲
• 韓國
• ASEAN
• 其他亞太地區
• 拉丁美洲
• 巴西
• 阿根廷
• 墨西哥
• 其他拉丁美洲
• 中東
• 海灣合作理事會國家
• 以色列
• 其他中東地區
• 非洲
• 北非
• 中部非洲
• 南非

第8章 競爭形勢

• Pfizer Inc.
  • Drug Class Portfolio
• Merck & Co., Inc.
• GlaxoSmithKline plc（GSK）
• AstraZeneca plc
• Novartis AG
• Johnson & Johnson
• Sanofi SA
• Bayer AG
• Basilea Pharmaceutica

第9章 章節

• 調查方法
• 關於出版商

The global acinetobacter pneumonia therapeutics market size is expected to reach US$ 899.1 Mn by 2030, from US$ 614.6 Mn in 2023, exhibiting a CAGR of 5.6% during the forecast period.

Figure 1. Global Acinetobacter Pneumonia Therapeutics Market Share (%), By Region, 2023

Acinetobacter pneumonia is a severe type of pneumonia caused by the Acinetobacter species of bacteria. These bacteria are commonly found in soil and water. In recent times, there has been a steep rise in the number of cases of hospital-acquired pneumonia caused by multidrug-resistant Acinetobacter strains. Typically, it affects immunocompromised patients or those on mechanical ventilation in intensive care units. Antibiotic resistance has emerged as a major challenge in treating Acinetobacter pneumonia. Novel therapeutic approaches targeting this pathogen are the need of the hour.

Market Dynamics:

The global Acinetobacter pneumonia therapeutics market is driven by the growing prevalence of drug-resistant strains and increasing incidence of hospital-acquired or ventilator-associated pneumonia. According to the Centers for Disease Control and Prevention, Acinetobacter infections account for 8-10% of all hospital-acquired pneumonia cases in the U.S. every year. Moreover, the restricted antibacterial pipeline and lack of approved therapies specific to Acinetobacter pneumonia act as opportunities in the market. However, high development costs and regulatory hurdles associated with new drug approvals hamper the market growth. The market is influenced by factors such as increasing incidence of multidrug-resistant strains, advancements in diagnostic technologies, and the need for effective treatment options. Collaborations between pharmaceutical companies, research institutions, and healthcare providers play a crucial role in advancing therapeutic solutions. The evolving landscape of infectious diseases and the impact of the COVID-19 pandemic underscore the importance of sustained efforts to address Acinetobacter pneumonia through innovative therapeutic interventions and public health measures.

Key Features of the Study:

This report provides an in-depth analysis of the global acinetobacter pneumonia therapeutics market, and provides market size (US$ Million) and compound annual growth rate (CAGR %) for the forecast period (2023-2030), considering 2022 as the base year

It elucidates potential revenue growth opportunities across different segments and explains attractive investment proposition matrices for this market

This study also provides key insights about market drivers, restraints, opportunities, new product launches or approvals, market trends, regional outlook, and competitive strategies adopted by key players

It profiles key players in the global acinetobacter pneumonia therapeutics market based on the following parameters - company highlights, products portfolio, key highlights, financial performance, and strategies

Key companies covered as a part of this study include Pfizer Inc., Merck & Co., Inc., GlaxoSmithKline plc (GSK), AstraZeneca plc, Novartis AG, Johnson & Johnson, Sanofi S.A., Bayer AG, and Basilea Pharmaceutica

Insights from this report would allow marketers and the management authorities of the companies to make informed decisions regarding their future product launches, type up-gradation, market expansion, and marketing tactics

The global acinetobacter pneumonia therapeutics market report caters to various stakeholders in this industry including investors, suppliers, product manufacturers, distributors, new entrants, and financial analysts

Stakeholders would have ease in decision-making through various strategy matrices used in analyzing the global acinetobacter pneumonia therapeutics market.

Detailed Segmentation:

• Global Acinetobacter Pneumonia Therapeutics Market, By Drug Class
  • Cephalosporins
  • Carbapenems
  • Aminoglycosides
  • Polymyxins
• Global Acinetobacter Pneumonia Therapeutics Market, By Route of Administration
  • Oral
  • Intravenous
  • Others
• Global Acinetobacter Pneumonia Therapeutics Market, By Region
  • North America
  • Europe
  • Asia Pacific
  • Latin America
  • Middle East
  • Africa
• Global Acinetobacter Pneumonia Therapeutics Market, Key Players
  • Pfizer Inc.
  • Merck & Co., Inc.
  • GlaxoSmithKline plc (GSK)
  • AstraZeneca plc
  • Novartis AG
  • Johnson & Johnson
  • Sanofi S.A.
  • Bayer AG
  • Basilea Pharmaceutica

Table of Contents

1. Research Objectives and Assumptions

• Research Objectives
• Assumptions
• Abbreviations

2. Market Purview

• Report Description
  • Market Definition and Scope
• Executive Summary
  • Global Acinetobacter Pneumonia Therapeutics Market, By Drug Class
  • Global Acinetobacter Pneumonia Therapeutics Market, By Route of Administration
  • Global Acinetobacter Pneumonia Therapeutics Market, By Region
• Coherent Opportunity Map (COM)

3. Market Dynamics, Regulations, and Trends Analysis

• Market Dynamics
  • Rising prevalence of Acinetobacter pneumonia infections
  • Increasing research & development activities
  • Growing healthcare expenditure
• Impact Analysis
• Key Highlights
• Regulatory Scenario
• Service offering Portfolio
• PEST Analysis
• PORTER's Analysis
• Merger and Acquisition Scenario
• Pipeline Analysis

4. Global Acinetobacter Pneumonia Therapeutics Market - Impact of Coronavirus (COVID-19) Pandemic

• COVID-19 Epidemiology
• Supply Side and Demand Side Analysis
• Economic Impact

5. Global Acinetobacter Pneumonia Therapeutics Market, By Drug Class, 2018-2030, (US$ Mn)

• Introduction
  • Market Share Analysis, 2023 and 2030 (%)
  • Y-o-Y Growth Analysis, 2019 - 2030
  • Segment Trends
• Cephalosporins
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, 2018-2030,(US$ Mn)
• Carbapenems
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, 2018-2030,(US$ Mn)
• Aminoglycosides
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, 2018-2030,(US$ Mn)
• Polymyxins
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, 2018-2030,(US$ Mn)

6. Global Acinetobacter Pneumonia Therapeutics Market, By Route of Administration, 2018-2030, (US$ Mn)

• Introduction
  • Market Share Analysis, 2023 and 2030 (%)
  • Y-o-Y Growth Analysis, 2019 - 2030
  • Segment Trends
• Oral
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, 2018-2030,(US$ Mn)
• Intravenous
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, 2018-2030,(US$ Mn)
• Others
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, 2018-2030,(US$ Mn)

7. Global Acinetobacter Pneumonia Therapeutics Market, By Region, 2018-2030, (US$ Mn)

• Introduction
  • Market Share Analysis, By Region, 2023 and 2030 (%)
  • Y-o-Y Growth Analysis, For Region, 2019 - 2030
  • Country Trends
• North America
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, By Drug Class, 2018-2030,(US$ Mn)
  • Market Size and Forecast, and Y-o-Y Growth, By Route of Administration, 2018-2030,(US$ Mn)
  • Market Size and Forecast, and Y-o-Y Growth, By Country, 2018-2030,(US$ Mn)
• U.S.
• Canada
• Europe
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, By Drug Class, 2018-2030,(US$ Mn)
  • Market Size and Forecast, and Y-o-Y Growth, By Route of Administration, 2018-2030,(US$ Mn)
  • Market Size and Forecast, and Y-o-Y Growth, By Country, 2018-2030,(US$ Mn)
• Germany
• U.K.
• Spain
• France
• Italy
• Russia
• Rest of Europe
• Asia Pacific
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, By Drug Class, 2018-2030,(US$ Mn)
  • Market Size and Forecast, and Y-o-Y Growth, By Route of Administration, 2018-2030,(US$ Mn)
  • Market Size and Forecast, and Y-o-Y Growth, By Country, 2018-2030,(US$ Mn)
• China
• India
• Japan
• Australia
• South Korea
• ASEAN
• Rest of Asia Pacific
• Latin America
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, By Drug Class, 2018-2030,(US$ Mn)
  • Market Size and Forecast, and Y-o-Y Growth, By Route of Administration, 2018-2030,(US$ Mn)
  • Market Size and Forecast, and Y-o-Y Growth, By Country, 2018-2030,(US$ Mn)
• Brazil
• Argentina
• Mexico
• Rest of Latin America
• Middle East
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, By Drug Class, 2018-2030,(US$ Mn)
  • Market Size and Forecast, and Y-o-Y Growth, By Route of Administration, 2018-2030,(US$ Mn)
  • Market Size and Forecast, and Y-o-Y Growth, By Country, 2018-2030,(US$ Mn)
• GCC Countries
• Israel
• Rest of Middle East
• Africa
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, By Drug Class, 2018-2030,(US$ Mn)
  • Market Size and Forecast, and Y-o-Y Growth, By Route of Administration, 2018-2030,(US$ Mn)
  • Market Size and Forecast, and Y-o-Y Growth, By Country/Sub-region, 2018-2030,(US$ Mn)
• North Africa
• Central Africa
• South Africa

8. Competitive Landscape

• Pfizer Inc.
  • Company Highlights
  • Drug Class Portfolio
  • Key Highlights
  • Financial Performance
  • Strategies
• Merck & Co., Inc.
• GlaxoSmithKline plc (GSK)
• AstraZeneca plc
• Novartis AG
• Johnson & Johnson
• Sanofi S.A.
• Bayer AG
• Basilea Pharmaceutica
• Analyst Views

9. Section

• Research Methodology
• About us